FORMULATION ARTICLES

FORMULATION VIDEOS

Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.

NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk us through the challenges active delivery strategies pose, particularly as it relates to receptor selection, and the emerging technologies/tools that can help us achieve greater delivery specificity to the target cell type.

The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.

Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS